Veeva Systems today announced that Veeva DQS (Data Quality System) has aggregated and cleaned data for more than 1 million subjects in more than 1,000 studies to accelerate the delivery of analysis-ready data and trial insights. With more than 500,000 automated queries, Veeva DQS has saved thousands of hours in data reconciliation for sites and sponsors. Veeva DQS cleans data for more than 1 million subjects across over 1,000 studies.
"One key area for us is handling the increasing volume of data generated from our growing number of clinical trials," said Ibrahim Kamstrup-Akkaoui, vice president at Novo. "Veeva DQS can help us manage, format, clean, and prepare this data for submission more efficiently."
Veeva DQS enables next-generation clinical data management with advancements essential for adopting the risk-based strategies recommended in regulatory guidelines, including ICH E6(R3). With innovations coming in Veeva DQS, clinical teams can gain high-quality data faster by automating data workflows, classifying and visualizing critical data, and driving orchestration of risk-based actions while eliminating manual reconciliation, enable risk-based quality management (RBQM) with automated data exchange between Veeva DQS and Veeva CTMS streamlining risk-based monitoring by alerting operations teams to key data changes like protocol deviations and allowing calculation of KRIs, and classify with data- and user-aware AI embedding AI to speed classification and understand purpose and criticality generating reports, listings, test scripts and custom workflows.
"With increasing data sources and growing protocol complexity, sponsors and CROs are using Veeva DQS to automate data workflows at scale across studies of all sizes," said Pavel Burmenko, lead, Veeva DQS strategy.
About Veeva Systems
Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves.
